KLF4 suppresses the proliferation of perihilar cholangiocarcinoma by negatively regulating GDF15 and phosphorylating AKT

Zhang,Xiaoming; Wang,Weijia; Lu,Chunlei; Zhang,Haifeng

doi:10.3892/or.2023.8659

KLF4 suppresses the proliferation of perihilar cholangiocarcinoma by negatively regulating GDF15 and phosphorylating AKT

Authors:
- Xiaoming Zhang
- Weijia Wang
- Chunlei Lu
- Haifeng Zhang
View Affiliations

Affiliations: General Surgery Center of Linyi People's Hospital, Linyi, Shandong 276000, P.R. China
Published online on: November 6, 2023 https://doi.org/10.3892/or.2023.8659
Article Number: 222
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Krüppel‑like factor 4 (KLF4) is a transcription factor which functions as a tumor suppressor or an oncogene in numerous types of solid tumors. However, its expression levels and function in perihilar cholangiocarcinoma (pCCA) have yet to be elucidated. In the present study, in order to investigate its roles in pCCA, reverse transcription‑quantitative PCR (RT‑qPCR), western blot analysis and immunohistochemistry were used to detect KLF4 expression in pCCA. The Chi‑squared test was used to analyze the associations between KLF4 and the clinicopathological features of patients with pCCA. Univariate and multivariate analyses were subsequently used to analyze the prognostic significance of KLF4. The tumor suppression of KLF4 was investigated for the purposes of illustrating its biological function both in vitro and in vivo. Furthermore, the association between KLF4 and growth/differentiation factor 15 (GDF15) was determined using pCCA tissue microarray (TMA) analysis and RT‑qPCR. The underlying molecular mechanisms between KLF4 and GDF15 were subsequently investigated in vitro. In pCCA tissues, KLF4 was found to be downregulated, and this was negatively associated with the histological grade and tumor size. The knockdown of KLF4 was also found to be a prognostic indicator of the poorer survival of patients with pCCA. Based on in vitro and in vivo analyses, KLF4 was found to suppress tumor progression and induce cell apoptosis. Furthermore, it was found that KLF4 executed its tumor suppressive effects via the regulation of the GDF15/AKT signaling pathway. Taken together, the findings of the present study demonstrate that KLF4 may be considered as an independent biomarker of a favorable prognosis of patients with pCCA, and the KLF4/GDF15/AKT signaling pathway may potentially be a novel molecular therapeutic target for patients with pCCA.

View Figures

View References

1	Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, Wongkham S and Gores GJ: Cholangiocarcinoma. Nat Rev Dis Primers. 7:652021. View Article : Google Scholar : PubMed/NCBI
2	Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, et al: Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 17:557–588. 2020. View Article : Google Scholar : PubMed/NCBI
3	Krasinskas AM: Cholangiocarcinoma. Surg Pathol Clin. 11:403–429. 2018. View Article : Google Scholar : PubMed/NCBI
4	Rizvi S and Gores GJ: Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
5	Khan AS and Dageforde LA: Cholangiocarcinoma. Surg Clin North Am. 99:315–335. 2019. View Article : Google Scholar : PubMed/NCBI
6	Deoliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ and Schulick RD: Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann Surg. 245:755–762. 2007. View Article : Google Scholar : PubMed/NCBI
7	Groot Koerkamp B, Wiggers JK, Gonen M, Doussot A, Allen PJ, Besselink MG, Blumgart LH, Busch OR, D'angelica MI, DeMatteo RP, et al: Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram. Ann Oncol. 27:7532016. View Article : Google Scholar : PubMed/NCBI
8	Ghaleb AM and Yang VW: Krüppel-like factor 4 (KLF4): What we currently know. Gene. 611:27–37. 2017. View Article : Google Scholar : PubMed/NCBI
9	Luo X, Zhang Y, Meng Y, Ji M and Wang Y: Prognostic significance of KLF4 in solid tumours: An updated meta-analysis. BMC Cancer. 22:1812022. View Article : Google Scholar : PubMed/NCBI
10	Wang N, Liu ZH, Ding F, Wang XQ, Zhou CN and Wu M: Down-regulation of gut-enriched Kruppel-like factor expression in esophageal cancer. World J Gastroenterol. 8:966–970. 2002. View Article : Google Scholar : PubMed/NCBI
11	Wei D, Kanai M, Huang S and Xie K: Emerging role of KLF4 in human gastrointestinal cancer. Carcinogenesis. 27:23–31. 2006. View Article : Google Scholar : PubMed/NCBI
12	Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE and Yang VW: Identification of Krüppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene. 23:395–402. 2004. View Article : Google Scholar : PubMed/NCBI
13	Ohnishi S, Ohnami S, Laub F, Aoki K, Suzuki K, Kanai Y, Haga K, Asaka M, Ramirez F and Yoshida T: Downregulation and growth inhibitory effect of epithelial-type Krüppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem Biophys Res Commun. 308:251–256. 2003. View Article : Google Scholar : PubMed/NCBI
14	Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, Chhieng DC, Grizzle WE, Engler JA, Krontiras H, et al: Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin Cancer Res. 10:2709–2719. 2004. View Article : Google Scholar : PubMed/NCBI
15	Jiang Z, Zhang Y, Chen X, Wu P and Chen D: Long non-coding RNA LINC00673 silencing inhibits proliferation and drug resistance of prostate cancer cells via decreasing KLF4 promoter methylation. J Cell Mol Med. 24:1878–1892. 2020. View Article : Google Scholar : PubMed/NCBI
16	Zhao C, Li Y, Qiu W, He F, Zhang W, Zhao D, Zhang Z, Zhang E, Ma P, Liu Y, et al: C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation. Oncogene. 37:4821–4837. 2018. View Article : Google Scholar : PubMed/NCBI
17	Li S, Ma YM, Zheng PS and Zhang P: GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2. J Exp Clin Cancer Res. 37:802018. View Article : Google Scholar : PubMed/NCBI
18	Xu Q, Xu HX, Li JP, Wang S, Fu Z, Jia J, Wang L, Zhu ZF, Lu R and Yao Z: Growth differentiation factor 15 induces growth and metastasis of human liver cancer stem-like cells via AKT/GSK-3β/β-catenin signaling. Oncotarget. 8:16972–16987. 2017. View Article : Google Scholar : PubMed/NCBI
19	Jin Y, Jung SN, Lim MA, Oh C, Piao Y, Kim HJ, Liu L, Kang YE, Chang JW, Won HR, et al: Transcriptional regulation of GDF15 by EGR1 promotes head and neck cancer progression through a positive feedback loop. Int J Mol Sci. 22:111512021. View Article : Google Scholar : PubMed/NCBI
20	Dong G, Huang X, Jiang S, Ni L, Ma L, Zhu C and Chen S: SCAP mediated GDF15-induced invasion and EMT of esophageal cancer. Front Oncol. 10:5647852020. View Article : Google Scholar : PubMed/NCBI
21	Joshi JP, Brown NE, Griner SE and Nahta R: Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. Biochem Pharmacol. 82:1090–1099. 2011. View Article : Google Scholar : PubMed/NCBI
22	Huang M, Narita S, Koizumi A, Nara T, Numakura K, Satoh S, Nanjo H and Habuchi T: Macrophage inhibitory cytokine-1 induced by a high-fat diet promotes prostate cancer progression by stimulating tumor-promoting cytokine production from tumor stromal cells. Cancer Commun (Lond). 41:389–403. 2021. View Article : Google Scholar : PubMed/NCBI
23	Yan Y, Yue X, Yang S, Zhao Z, Wu P and Liu H: The expression of growth differentiation factor 15 in gallbladder carcinoma. J BUON. 26:218–228. 2021.PubMed/NCBI
24	Li C, Wang J, Kong J, Tang J, Wu Y, Xu E, Zhang H and Lai M: GDF15 promotes EMT and metastasis in colorectal cancer. Oncotarget. 7:860–872. 2016. View Article : Google Scholar : PubMed/NCBI
25	Wang X, Baek SJ and Eling TE: The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochem Pharmacol. 85:597–606. 2013. View Article : Google Scholar : PubMed/NCBI
26	Fang L, Li F and Gu C: GDF-15: A multifunctional modulator and potential therapeutic target in cancer. Curr Pharm Des. 25:654–662. 2019. View Article : Google Scholar : PubMed/NCBI
27	Yang Y, Goldstein BG, Chao HH and Katz JP: KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol Ther. 4:1216–1221. 2005. View Article : Google Scholar : PubMed/NCBI
28	Li JC, Chen QH, Jian R, Zhou JR, Xu Y, Lu F, Li JQ and Zhang H: The partial role of KLF4 and KLF5 in gastrointestinal tumors. Gastroenterol Res Pract. 2021:24253562021. View Article : Google Scholar : PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
30	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI
31	Razumilava N and Gores GJ: Cholangiocarcinoma. Lancet. 383:2168–2179. 2014. View Article : Google Scholar : PubMed/NCBI
32	Zhang XM, Liu ZL, Qiu B, Xu YF, Pan C and Zhang ZL: Downregulation of EVI1 expression inhibits cell proliferation and induces apoptosis in hilar cholangiocarcinoma via the PTEN/AKT signalling pathway. J Cancer. 11:1412–1423. 2020. View Article : Google Scholar : PubMed/NCBI
33	Guo K, Cui J, Quan M, Xie D, Jia Z, Wei D, Wang L, Gao Y, Ma Q and Xie K: The novel KLF4/MSI2 signaling pathway regulates growth and metastasis of pancreatic cancer. Clin Cancer Res. 23:687–696. 2017. View Article : Google Scholar : PubMed/NCBI
34	Rowland BD, Bernards R and Peeper DS: The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol. 7:1074–1082. 2005. View Article : Google Scholar : PubMed/NCBI
35	Hu W, Hofstetter WL, Li H, Zhou Y, He Y, Pataer A, Wang L, Xie K, Swisher SG and Fang B: Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma. Clin Cancer Res. 15:5688–5695. 2009. View Article : Google Scholar : PubMed/NCBI
36	Patel NV, Ghaleb AM, Nandan MO and Yang VW: Expression of the tumor suppressor Krüppel-like factor 4 as a prognostic predictor for colon cancer. Cancer Epidemiol Biomarkers Prev. 19:2631–2638. 2010. View Article : Google Scholar : PubMed/NCBI
37	Chen YJ, Wu CY, Chang CC, Ma CJ, Li MC and Chen CM: Nuclear Krüppel-like factor 4 expression is associated with human skin squamous cell carcinoma progression and metastasis. Cancer Biol Ther. 7:777–782. 2008. View Article : Google Scholar : PubMed/NCBI
38	Hu W, Jia Y, Xiao X, Lv K, Chen Y, Wang L, Luo X, Liu T, Li W, Li Y, et al: KLF4 downregulates hTERT expression and telomerase activity to inhibit lung carcinoma growth. Oncotarget. 7:52870–52887. 2016. View Article : Google Scholar : PubMed/NCBI
39	Rowland BD and Peeper DS: KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer. 6:11–23. 2006. View Article : Google Scholar : PubMed/NCBI
40	Ghaleb AM, McConnell BB, Kaestner KH and Yang VW: Altered intestinal epithelial homeostasis in mice with intestine-specific deletion of the Krüppel-like factor 4 gene. Dev Biol. 349:310–320. 2011. View Article : Google Scholar : PubMed/NCBI
41	Cui J, Shi M, Quan M and Xie K: Regulation of EMT by KLF4 in gastrointestinal cancer. Curr Cancer Drug Targets. 13:986–999. 2013. View Article : Google Scholar : PubMed/NCBI
42	Modi A, Purohit P, Roy D, Vishnoi JR, Pareek P, Elhence P, Singh P, Sharma S, Sharma P and Misra S: FOXM1 mediates GDF-15 dependent stemness and intrinsic drug resistance in breast cancer. Mol Biol Rep. 49:2877–2888. 2022. View Article : Google Scholar : PubMed/NCBI
43	Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI